News und Analysen
![Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six e-posters highlighting clinical data from the lucitanib and Rubraca® (rucaparib) clinical development programs, as well as preclinical
![Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Xencor to Present Initial Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that initial
![Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Pfizer and BioNTech Announce Data from Preclinical Studies of mRNA-based Vaccine Candidate Against COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary preclinical data in mouse and non-human primate models from their BNT162b2 mRNA-based vaccine program against
![NanoString Announces New GeoMx COVID-19 Consortium, Part of the GeoMx Translational Leadership Network](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
NanoString Announces New GeoMx COVID-19 Consortium, Part of the GeoMx Translational Leadership Network
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced the formation of the GeoMx Translational Leadership
![Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Pfizer and BioNTech to Potentially Supply the EU with 200 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that they had concluded exploratory talks with the European Commission for a proposed supply of 200 million doses of their
![Albireo Pharma: SD-Jubiläumsrakete liefert +115%](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Albireo Pharma: SD-Jubiläumsrakete liefert +115%
Unsere Jubiläumsrakete Albireo Pharma (WKN: A2DF99) knallte gestern dank positiver Studienergebnisse auf bis zu 49,00 US-Dollar und damit 115% auf unseren Empfehlungskurs von 22,78 US-Dollar – was
![Sirona Biochem beauftragt WuXi AppTec mit der Herstellung von TFC-1067 im Großmaßstab](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Sirona Biochem beauftragt WuXi AppTec mit der Herstellung von TFC-1067 im Großmaßstab
Vancouver, British Columbia – 9. September 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (US-OTC: SRBCF) („Sirona“) freut sich bekannt zu geben, dass das Unternehmen eine Vereinbarung
![Sirona Biochem Contracts WuXi AppTec for Large-Scale Manufacturing of TFC-1067](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Sirona Biochem Contracts WuXi AppTec for Large-Scale Manufacturing of TFC-1067
Vancouver, British Columbia – September 9, 2020 – Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (“Sirona”) is pleased to announce it has signed an agreement with Contract Manuf
![Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
![Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its President and Chief Executive Officer, Patrick J. Mahaffy, will present at the H.C. Wainwright 22nd Annual Global Investment Conference
![QIAGEN führt portablen Schnelltest ein, der mehr als 30 Proben pro Stunde auf das SARS-CoV-2-Antigen untersuchen kann](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
QIAGEN führt portablen Schnelltest ein, der mehr als 30 Proben pro Stunde auf das SARS-CoV-2-Antigen untersuchen kann
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute Pläne zur Einführung eines portablen Schnelltests bekannt gegeben, der mittels eines kleinen digitalen Testsystems SARS-CoV-2-Antigene
![Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Navidea Biopharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
QIAGEN to Launch Rapid Portable Test That Can Analyze Over 30 Samples Per Hour for SARS-CoV-2 Antigen
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to launch a rapid portable test that can detect SARS-CoV-2 antigens in people with active infections in less than 15 minutes
![Positive Initial Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Positive Initial Data From a Phase 1 Trial With Transgene’s Oncolytic Virus TG6002
Regulatory News:
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces first positive data from the Phase
![Charles River Laboratories to Present at September Investor Conferences](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Charles River Laboratories to Present at September Investor Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:
-
Wells Fargo 2020 Healthcare
![Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled “Inhaled Molgramostim
![Biopharma Leaders Unite to Stand with Science](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States
![Canopy Growth: Neuer Online-Store, aber bekannte Zahlenschwäche...](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Canopy Growth: Neuer Online-Store, aber bekannte Zahlenschwäche...
Canopy Growth (WKN: A140QA) goes online: Mit dem neuen Online-Store ShopCanopy versucht das Unternehmen aus Smith Falls, Kanada, seine E-Commerce-Aktivitäten zu intensivieren.
Doch bei einem
![THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, September 7, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
![CO.DON AG: Treatment of patients starts in Switzerland](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
CO.DON AG: Treatment of patients starts in Switzerland
Berlin / Teltow / Leipzig, 07 September 2020 – The INSELSPITAL in Bern, Bern’s university hospital, has become the first Swiss clinic to start treating patients with the 100% autologous
![CO.DON AG: Behandlung von Patienten in der Schweiz begonnen](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
CO.DON AG: Behandlung von Patienten in der Schweiz begonnen
Berlin / Teltow / Leipzig, 07. September 2020 – Das INSELSPITAL Bern, Universitätsspital der Universität Bern hat als erste Schweizer Klinik mit der Behandlung von Patienten mit dem 100 %
![Relay & Fio Corp. prüfen Marktentwicklung und COVID-19-Anwendungen für Fionet](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Relay & Fio Corp. prüfen Marktentwicklung und COVID-19-Anwendungen für Fionet
- Regierung, Medien und Ärzte stimmen sich über die Notwendigkeit von routinemäßigen, kontrollierten Tests an Flughäfen, Arbeitsplätzen, zu Hause und an anderen dezentralen Orten
![Relay & Fio Corp. Address Market Development and Fionet COVID-19 Applications](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Relay & Fio Corp. Address Market Development and Fionet COVID-19 Applications
- Government, Media, and Doctors Are Aligning on Need for Routine, Controlled Testing at Airports, Workplaces, Homes, and Other Decentralized Locations
- Health Canada
![Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer